Physician profile
Smith Giri
NPI 1275975534
$50,366.06
in general payments reported to CMS, 2019-2025
45 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,314 · 2022: $5,103 · 2023: $1,650 · 2024: $24K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $16K · Food and Beverage: $2,774 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,439.00 |
| Consulting Fee | $15,657.98 |
| Food and Beverage | $2,774.09 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32,166.43 | 2021-2025 | |
| Janssen Research & Development, LLC | $10,507.98 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $5,150.00 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Novartis Pharmaceuticals Corporation | $208.45 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $202.00 | 2025 | Imfinzi, Lynparza, Calquence |
| Pfizer INC. | $157.51 | 2025 | |
| Abbvie INC. | $130.80 | 2025 | |
| Incyte Corporation | $118.99 | 2025 | Jakafi |
| Genentech USA, INC. | $116.85 | 2025 | Tecentriq, Venclexta, Polivy |
| E.R. Squibb & Sons, L.L.C. | $108.86 | 2025 | Opdivo |
| Janssen Biotech, INC. | $103.90 | 2025 | Darzalex, Talvey, Carvykti |
| Novocure INC. | $88.84 | 2025 | Optune Lua (Novottf-200t) |
| Glaxosmithkline, LLC. | $86.14 | 2025 | Ojjaara, Blenrep, Jemperli |
| Regeneron Healthcare Solutions, INC. | $82.85 | 2025 | Lynozyfic, Libtayo |
| Merck Sharp & Dohme LLC | $78.64 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smith Giri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.